News | June 08, 2015

Mevion Medical Systems First to Open Back-to-Back Proton Therapy Centers

New Jersey’s Robert Wood Johnson University Hospital treats first patients with the Mevion S250 system weeks after Ackerman Cancer Center in Florida

Mevion, S250, Robert Wood Johnson University Hospital, back-to-back, proton

June 8, 2015 - The Mevion S250 proton therapy system at Robert Wood Johnson University Hospital (RWJUH) is now treating patients, less than four weeks after the first Mevion patient was treated at Ackerman Cancer Center. The occasion marks the first time a proton manufacturer has simultaneously brought up two distinct facilities.

The first two patients treated at RWJUH included a young man with a spinal myxopapillary ependymoma, a cancer that affects the spinal canal. His treatment began on June 5. A second patient with a recurrent brain tumor began treatment on May 27; this patient had received full doses of radiation in the past, and re-treating him with other technologies would have proved difficult. RWJUH, in New Brunswick, New Jersey, is the flagship Cancer Hospital of Rutgers Cancer Institute of New Jersey and the principal teaching hospital of Rutgers Robert Wood Johnson Medical School.

Proton therapy provides targeted treatment to cancer cells and causes less damage to surrounding healthy tissues than photon radiation. This makes it an ideal option for pediatric and adult patients with tumors in sensitive locations, such as near the heart, brain and spine.

Traditionally, proton therapy systems have required the development of new football-field-sized facilities that have ended up costing hundreds of millions of dollars to build and operate. Because only a limited number of cancer centers have this kind of capital or space, there has been a lack of patient access to this important treatment modality. The Mevion S250 is the world's smallest single-room proton therapy system and can be readily integrated into any size cancer facility – existing or new. The result is a proton therapy solution that is 75 percent smaller and uses as much as 90 percent less energy, resulting in significantly lower capital and operating costs.

"The MEVION S250 provides RWJUH with a compact, high-quality delivery system to include in our suite of patient treatment options," said Bruce Haffty, M.D., chief of radiation oncology at RWJUH and professor and chairman of the Department of Radiation Oncology at the Cancer Institute of New Jersey, Robert Wood Johnson Medical School and New Jersey Medical School at Rutgers University. "This is an important milestone in cancer therapy for patients in this region. We can now treat patients in less time with fewer side effects with a very targeted form of radiation therapy."

RWJUH is fully accredited by the American College of Surgeons Commission on Cancer.

"We always strive for excellence in cancer treatment," said Atif Khan, M.D., a radiation oncologist at Rutgers Cancer Institute of New Jersey and associate professor of radiation oncology at Rutgers Robert Wood Johnson Medical School. "I am excited to see the benefits that the Mevion S250 brings to the patients at our proton center."

The S250 began treating patients at Ackerman Cancer Center - a physician-owned facility in Jacksonville, Florida - on April 30 and is currently treating 24 patients per day. Mevion S250 systems are currently being installed at four additional sites in the United States, including University Hospitals Health System in Cleveland, where the superconducting synchrocyclotron accelerator is scheduled to be delivered at the end of June. Other installation sites are: Stephenson Cancer Center at the University of Oklahoma in Oklahoma City; University of Florida Health Cancer Center at Orlando Health; and MedStar Georgetown University Hospital's Lombardi Comprehensive Cancer Center in Washington, D.C.

For more information: www.mevion.com

Related Content

Stronger Distribution Networks to Bolster Radiotherapy Patient Positioning Accessories
News | Patient Positioning Radiation Therapy | July 19, 2019
A recent study projects global market revenues for radiotherapy patient positioning accessories will exceed revenues of...
CMS Proposes New Alternative Payment Model for Radiation Oncology
News | Radiation Oncology | July 17, 2019
The Centers for Medicare and Medicaid Services (CMS) issued a proposal for an advanced alternative payment model (APM)...
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
RaySearch Releases Version 3A of RayCare Oncology Information System
Technology | Oncology Information Management Systems (OIMS) | July 15, 2019
RaySearch has released RayCare 3A, a new version of the next-generation oncology information system (OIS). RayCare is...
IBA Launches Monte Carlo Patient QA for Varian Halcyon at AAPM 2019
Technology | Quality Assurance (QA) | July 10, 2019
IBA announced the launch of the latest functionality of the SciMoCa Monte Carlo Patient QA solution at the 61st annual...
Researchers Use Artificial Intelligence to Deliver Personalized Radiation Therapy
News | Radiation Therapy | July 09, 2019
New Cleveland Clinic-led research shows that artificial intelligence (AI) can use medical scans and health records to...
The Beamscan 3-D water phantom with the Varian Halcyon radiotherapy system

The Beamscan 3-D water phantom with the Varian Halcyon radiotherapy system. Image courtesy of PTW.

News | Quality Assurance (QA) | July 08, 2019
At this year’s American Association of Physicists in Medicine (AAPM) show, July 14-18 in San Antonio, Texas, PTW will...
Aktina Medical Partners With Elekta for Global Distribution of Interlocking SRS Cones
News | Radiation Therapy | July 05, 2019
Aktina Medical announced that Elekta Instrument AB, based in Sweden, will offer and distribute the Aktina line of...